SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSED IN A PHASE 1b CLINICAL TRIAL OF SM17 IN CHINA

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") on 16 February 2022, 14 March 2022, 15 June 2022, 22 May 2023, 12 June 2023, 14 August 2023, 11 September 2023 and 27 November 2023 in relation to the latest research and development progress of one of the Group's key products, SM17.

The board of directors (the "**Board**") of the Company is pleased to announce that, on 5 June 2024, the first patient has been successfully dosed in a phase 1b clinical trial of SM17 for the treatment of Atopic Dermatitis ("**AD**") in China. As of the date of this announcement, no adverse event was observed. The phase 1b trial aims to study safety, tolerability and pharmacokinetics (PK) profiles of SM17, as well as to explore the preliminary efficacy of SM17 in AD patients.

SM17 is a novel, First-in-Class (FIC), humanized, IgG4-κ monoclonal antibody which is capable of modulating Type II allergic reaction by targeting the receptor of a critical "alarmin" molecule interleukin 25 (IL-25). SM17 could suppress Type 2 helper T (Th2) immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s) and Th2 cells, to block a cascade of responses induced by IL-25 and suppress the release of the downstream Th2 cytokines such as IL-4, IL-5 and IL-13.

IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, such as AD. Patients with AD also have an increasing all-cause mortality rate and disease-specific mortality rate in the following diseases, which include infections, respiratory diseases, gastrointestinal diseases and oncologic diseases. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient's quality of life. However, there is still an unmet medical need for patients showing irresponsiveness to those approved therapies.

The Company performed a first-in-human Phase I clinical trial (NCT05332834) in the US to evaluate the safety and tolerability of SM17 in healthy subjects. Clinical report obtained in the first quarter of 2024 revealed a good safety profile of SM17 with no drug-related serious adverse event reported. To allow for clinical studies in China, a phase 1a bridging study was also initiated in China that demonstrated SM17 to exhibit similar and comparable safety profile in both the US and the Chinese population. To validate the results of preclinical studies published in an international scientific journal *Allergy* that demonstrated SM17 to be as effective as JAK1 inhibitor in treating AD in mice, it is therefore important that a phase 1b corroborative and proof-of-concept study is performed.

The Company believes that therapies targeting upstream of the Th2 inflammatory cytokine pathway, such as IL-25 receptor, will have broad effects on skin inflammation, implicating a great potential for SM17 as a differentiating, safer and more effective products for the treatment of AD.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 11 June 2024

As at the date of this announcement, the executive directors are Dr. Shui On LEUNG and Mr. Shanchun WANG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Dr. Wenyi LIU, Mr. Lei SHI and Dr. Jianmin ZHANG, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.